tetano
Editor, Senior Moderator
Emerg Infect Dis. 2010 Jul;16(7):1185-6.
Oseltamivir-Resistant Pandemic (H1N1) 2009 in Patient with Impaired Immune System.
Hill-Cawthorne GA, Schelenz S, Lawes M, Dervisevic S.
University of East Anglia, Norwich, UK; and Norfolk and Norwich University Hospital, Norwich.
Abstract
To the Editor: We detail the development of oseltamivir-resistant pandemic (H1N1) 2009 in a chronically immunocompromised patient and the pitfalls encountered when treating such patients with neuraminidase inhibitors. On August 6, 2009, a 56-year-old man was seen in the emergency room of a local hospital with a 24-hour history of fever, myalgia, coryzal symptoms, and cough. He was on day 3 of a postexposure course of oseltamivir (75 mg 1x/d); influenza A had been presumptively diagnosed for his wife after she had similar symptoms.
PMID: 20587208 [PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/20587208
Oseltamivir-Resistant Pandemic (H1N1) 2009 in Patient with Impaired Immune System.
Hill-Cawthorne GA, Schelenz S, Lawes M, Dervisevic S.
University of East Anglia, Norwich, UK; and Norfolk and Norwich University Hospital, Norwich.
Abstract
To the Editor: We detail the development of oseltamivir-resistant pandemic (H1N1) 2009 in a chronically immunocompromised patient and the pitfalls encountered when treating such patients with neuraminidase inhibitors. On August 6, 2009, a 56-year-old man was seen in the emergency room of a local hospital with a 24-hour history of fever, myalgia, coryzal symptoms, and cough. He was on day 3 of a postexposure course of oseltamivir (75 mg 1x/d); influenza A had been presumptively diagnosed for his wife after she had similar symptoms.
PMID: 20587208 [PubMed - in process]
http://www.ncbi.nlm.nih.gov/pubmed/20587208